Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Ultragenyx Pharmaceutical Inc. (RARE : NSDQ)

• Company Description    Ultragenyx Pharmaceutical Inc. is focused on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Number of Employees: 1,371

• Price / Volume Information    Yesterday's Closing Price: $26.90 Daily Weekly Monthly 20 Day Moving Average: 2,902,031 shares Shares Outstanding: 98.49 (millions) Market Capitalization: $2,649.35 (millions) Beta: 0.31 52 Week High: $39.89 52 Week Low: $18.29 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.03% -8.71% 12 Week 8.95% 5.97% Year To Date 16.96% 8.55%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 60 Leveroni Court - Novato,CA 94949 USA ph: 415-483-8800 fax: 415-483-8810 ir@ultragenyx.com http://www.ultragenyx.com

• General Corporate Information    Officers Emil D. Kakkis - President and Chief Executive Officer Daniel G. Welch - Chairman Howard Horn - Executive Vice President; Chief Financial Officer; Theodore A. Huizenga - Senior Vice President and Chief Accounting Officer Deborah Dunsire - Director Peer Information Ultragenyx Pharmaceutical Inc. (CORR.) Ultragenyx Pharmaceutical Inc. (RSPI) Ultragenyx Pharmaceutical Inc. (CGXP) Ultragenyx Pharmaceutical Inc. (BGEN) Ultragenyx Pharmaceutical Inc. (GTBP) Ultragenyx Pharmaceutical Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 90400D108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/04/26 Share - Related Items Shares Outstanding: 98.49 Most Recent Split Date: (:1) Beta: 0.31 Market Capitalization: $2,649.35 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.85 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-4.53 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 31.91% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 3.96 EPS Growth vs. Year Ago Period: -17.20% vs. Previous Quarter: -42.64% Sales Growth vs. Year Ago Period: -2.36% vs. Previous Quarter: -34.30% ROE 06/30/26 - - 03/31/26 - - 12/31/25 - -1,024.42 ROA 06/30/26 - - 03/31/26 - -45.78 12/31/25 - -43.10 Current Ratio 06/30/26 - - 03/31/26 - 2.02 12/31/25 - 2.48 Quick Ratio 06/30/26 - - 03/31/26 - 1.85 12/31/25 - 2.34 Operating Margin 06/30/26 - - 03/31/26 - -91.03 12/31/25 - -85.54 Net Margin 06/30/26 - - 03/31/26 - -91.03 12/31/25 - -85.54 Pre-Tax Margin 06/30/26 - - 03/31/26 - -90.38 12/31/25 - -84.84 Book Value 06/30/26 - - 03/31/26 - -2.40 12/31/25 - -0.83 Inventory Turnover 06/30/26 - - 03/31/26 - 2.14 12/31/25 - 2.22 Debt-to-Equity 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Capital 06/30/26 - - 03/31/26 - - 12/31/25 - -

Powered by Zacks Investment Research ©